Ie-Ming Shih

HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis.

Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis.

Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin.

Genotype analysis using human hair shaft.

The Role of E-cadherin in the Motility and Invasion of Implantation Site Intermediate Trophoblast.

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Proteomic approaches to tumor marker discovery.

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Digital single-nucleotide polymorphism analysis for allelic imbalance.

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract.

Differential expression of L-selectin ligand in the endometrium during the menstrual cycle.

Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.

Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma.

Expression of L-selectin ligands in human endometrium during the implantation window after controlled ovarian stimulation for oocyte donation.

Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization.

Immunological localization of syndecan-1 in human endometrium throughout the menstrual cycle.

Application of human leukocyte antigen-G expression in the diagnosis of human cancer.

Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumorlike lesions.

Knowledge-guided multi-scale independent component analysis for biomarker identification.

Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

p53 autoantibodies, cytokine levels and ovarian carcinogenesis.

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.

Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Lack of a y-chromosomal complement in the majority of gestational trophoblastic neoplasms.

DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.

Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Are all pelvic (nonuterine) serous carcinomas of tubal origin?

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.

PUGSVM: a caBIGâ„¢ analytical tool for multiclass gene selection and predictive classification.

DDN: a caBIG® analytical tool for differential network analysis.

Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.

Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.

BACOM: in silico detection of genomic deletion types and correction of normal cell contamination in copy number data.

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Comparison of candidate serologic markers for type I and type II ovarian cancer.

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Mapping DNA Quantity into Electrophoretic Mobility through Quantum Dot Nanotethers for High-Resolution Genetic and Epigenetic Analysis.

Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.

Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.

Genome-wide identification of significant aberrations in cancer genome.

The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Pathogenesis and new therapeutic targets of ovarian cancer.

Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.

Polysialic acid enhances the migration and invasion of human cytotrophoblasts.

Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Identification of the NAC1-regulated genes in ovarian cancer.

Establishing isogenic inducible cell lines using founder reporter lines and recombinase-mediated cassette exchange.

AISAIC: a software suite for accurate identification of significant aberrations in cancers.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?

Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Long interspersed element-1 protein expression is a hallmark of many human cancers.

The emerging roles of ARID1A in tumor suppression.

Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.

BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.

Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer.

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.

Seromucinous Tumors of the Ovary. What's in a Name?

Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.

Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer.

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.

High grade serous ovarian carcinomas originate in the fallopian tube.

CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data.

International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group.

Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.

Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions.

Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions.

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function.

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.

Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment.

Follicular fluid has more to offer: Insulin-like growth factor axis on ovarian carcinogenesis.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.

Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.

The Origin and Pathogenesis of Endometriosis.

Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.

Oncogenic BRAF and KRAS mutations in endosalpingiosis.

-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.

Not All Peritoneal Implants Are Created Equal.

Low-grade serous ovarian cancer: State of the science.

Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression.

Assessing aneuploidy with repetitive element sequencing.

Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.

Methylomic Landscapes of Ovarian Cancer Precursor Lesions.

Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.

The Origin of Ovarian Cancer Species and Precancerous Landscape.

Pathology and Pathogenesis of Adenomyosis.

Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis.

Correction: -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.

Uterine serous carcinoma: key advances and novel treatment approaches.

A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening.

Mutation and methylation profiles of ectopic and eutopic endometrial tissues.

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy.

Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Serous tubal intra-epithelial carcinoma: what do we really know at this point?

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC).

Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis.

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker.

A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening.